Full-Time

Senior Scientist I

Dmpk

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS cancers

Compensation Overview

$144k - $180k/yr

Senior

San Carlos, CA, USA

Hybrid

Hybrid position requiring some in-office presence in Redwood City, CA.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • A highly motivated individual with a PhD in Pharmaceutic Sciences or a related scientific discipline, with 5 years of experience after graduation.
  • Solid knowledge and experience in the ADME/PK concepts and basic compartmental modeling software.
  • Prior experience with small molecule drug discovery programs experience working as a DMPK functional representative on cross-functional project teams.
  • Complete understanding of early- through late-stage development and commercial advancement.
  • Excellent verbal and written communication, problem-solving and critical thinking skills.
  • Thrives in a collaborative team setting and is driven by a desire to be innovative in a highly energetic and fast-paced environment.
Responsibilities
  • Participate in the discovery of novel tri-complex inhibitors of frontier oncology targets by planning and implementing DMPK strategies to drive key project decisions for advancing small molecule programs. E.g. soft-spot analysis in optimization of molecules with improved metabolic stability or permeability.
  • Maintain sufficient knowledge of principles and theories to serve as a DMPK technical lead on multi-disciplinary project teams.
  • Design, manage and trouble-shoot mechanistic in vitro ADME and PK studies in a timely manner, and discuss results and potential solutions/implications at internal meetings.
  • Conduct innovative research to understand the underlying principles of drug absorption, distribution, and elimination of RevMed TCI compounds by generating hypotheses from available data and literature. Incorporate new concepts and experimental techniques to develop novel in vitro ADME assays and refine IVIVE approaches.
  • Collaborate with external functions to provide input and guidance on the translation of nonclinical PK/PD, PK-efficacy and PK-safety relationships to humans.
  • Author and review DMPK sections of regulatory submissions and respond to questions from regulatory agencies.
  • Build and maintain strong collaborative partnerships across external functional areas, e.g., Medicinal chemistry, Biology, Cancer Pharmacology, Clinical Pharmacology.
Desired Qualifications
  • Prior experience with oncology drug development.
  • Industry experience of drug development is preferred.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to tailor their research and development efforts to this specific area. Their goal is to improve cancer treatment outcomes for patients with RAS mutations by providing effective targeted therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • $2 billion capital raise supports global expansion and commercialization strategies.
  • Acquisition of EQRx enhances market reach and competitive positioning.
  • Recognition for transformative pancreatic cancer research highlights leadership in oncology.

What critics are saying

  • EQRx acquisition may dilute focus on high-value cancer therapies.
  • Independent global strategy could strain resources and delay market entry.
  • $750 million debt facility increases financial risk if commercialization fails.

What makes Revolution Medicines unique

  • Revolution Medicines synthesizes pharmaceutically optimized analogues of complex natural products.
  • Their Tri Complex Inhibitor platform creates highly specialized cancer treatments.
  • Focus on RAS gene mutations addresses critical unmet medical needs in oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
MarketScreener
Jun 24th, 2025
Revolution Medicines, Inc Announces Debt Facility Up to $750 Million Senior Secured Term Loan

Revolution Medicines, Inc. announced that the debt facility up to $750 million senior secured term loan consisting of three $250 million tranches linked to commercialization of daraxonrasib. The...

BioWorld
Jun 24th, 2025
Revmed secures $2B for global expansion

Revolution Medicines (Revmed) has secured $2 billion in capital to develop its own global commercial infrastructure for RAS(ON) inhibitors, targeting RAS-addicted cancers. The company decided to independently manage its global development and commercial strategies, rather than partnering outside the U.S. as initially planned, according to CEO Mark Goldsmith.

BioWorld
Jun 24th, 2025
Revmed goes global with $2B in capital for RAS(ON) inhibitors

Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to build its own global commercial infrastructure, instead of partnering outside the U.S. as it had originally intended.

PRWeb
May 9th, 2025
The Lustgarten Foundation Honors Revolution Medicines For Transformative Research In Pancreatic Cancer

"Revolution Medicines exemplifies the power of bold science and collaboration in driving meaningful progress for patients," said Linda Tantawi, CEO of the Lustgarten Foundation

Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.